AZD3463 ALK/IGF1R Inhibitor: Mechanisms, Evidence, and Research Integration

Executive Summary:
AZD3463 is a potent, orally bioavailable small molecule inhibitor targeting ALK and IGF1R with high selectivity and low nanomolar affinity (Ki = 0.75 nM). It effectively suppresses proliferation of neuroblastoma cell lines, including those with activating ALK mutations (F1174L, D1091N), by blocking ALK-mediated PI3K/AKT/mTOR signaling (APExBIO). Combination with chemotherapeutics such as doxorubicin and temozolomide yields synergistic cytotoxicity in vitro. In vivo studies show tumor reduction in orthotopic neuroblastoma xenograft mouse models at 15 mg/kg dosing. AZD3463’s robust solubility in DMSO and stability at -20°C facilitate its integration into diverse experimental workflows (APExBIO).

Biological Rationale

Neuroblastoma is a pediatric malignancy characterized by aberrant activation of receptor tyrosine kinases, especially ALK (anaplastic lymphoma kinase). ALK activation drives tumor cell survival and proliferation via downstream pathways such as PI3K/AKT/mTOR. Mutations in ALK (notably F1174L and D1091N) are recurrent in high-risk neuroblastoma and confer resistance to first-generation ALK inhibitors (Chavali et al., 2020). IGF1R signaling also contributes to oncogenic processes and therapeutic resistance. Targeting both ALK and IGF1R provides a dual-mechanism approach for overcoming resistance and inducing tumor cell death. AZD3463, developed by APExBIO, specifically inhibits these kinases, making it a strategic tool for ALK-driven cancer research.

Mechanism of Action of AZD3463 ALK/IGF1R inhibitor

AZD3463 is a small molecule inhibitor with a molecular weight of 448.95 Da and chemical formula C₂₄H₂₅ClN₆O. It binds ALK and IGF1R at nanomolar affinity (Ki = 0.75 nM), leading to selective inhibition of their kinase activity (APExBIO). This blockade prevents phosphorylation and activation of the PI3K/AKT/mTOR signaling cascade, a central pathway in neuroblastoma pathogenesis. Inhibition of this pathway results in decreased cell proliferation, induction of apoptosis, and stimulation of autophagy. AZD3463 is effective against both wild-type and mutant (F1174L, D1091N) ALK forms, directly counteracting resistance mechanisms to earlier ALK inhibitors (Next-Generation ALK Inhibition). When combined with DNA-damaging agents like doxorubicin or temozolomide, AZD3463 enhances cytotoxic effects through synergistic mechanisms.

Evidence & Benchmarks

• AZD3463 inhibits ALK and IGF1R kinase activity with a Ki of 0.75 nM (APExBIO, product page).
• Suppresses neuroblastoma cell proliferation in vitro at 5–50 μM in both wild type and mutant ALK backgrounds (Chavali et al., 2020).
• Induces apoptosis and autophagy in neuroblastoma cells by blocking PI3K/AKT/mTOR signaling (AZD3463 and the Future of ALK/IGF1R Inhibition).
• In vivo, intraperitoneal administration at 15 mg/kg daily for two days reduces tumor growth in orthotopic xenograft mouse models (APExBIO).
• Combination with doxorubicin or temozolomide yields synergistic cytotoxicity in preclinical assays (AZD3463: Oral ALK Inhibitor for Neuroblastoma Research).

This article extends the mechanistic detail found in Next-Generation ALK Inhibition in Neuroblastoma by providing updated evidence on combination strategies and practical workflow integration.

Applications, Limits & Misconceptions

AZD3463 is primarily utilized in preclinical research for neuroblastoma and other ALK-driven malignancies. It is suitable for cell viability, apoptosis, and autophagy assays, as well as in vivo xenograft studies. The compound supports studies on overcoming resistance to first-generation ALK inhibitors and investigating combinatorial regimens with chemotherapeutics.

Common Pitfalls or Misconceptions

• AZD3463 is not water- or ethanol-soluble; use DMSO for stock solutions (≥11.22 mg/mL).
• It is not licensed for clinical or veterinary use—research applications only.
• Long-term storage of solutions (in DMSO) is not recommended; prepare fresh aliquots as needed.
• Effectiveness is limited in models lacking ALK or IGF1R expression.
• Not all resistance mutations may respond equally; empirical validation is necessary for novel variants.

This clarification builds on AZD3463 ALK/IGF1R Inhibitor: Data-Driven Solutions, which focuses on troubleshooting, by emphasizing chemical and application boundaries.

Workflow Integration & Parameters

AZD3463 (SKU A8620) from APExBIO can be integrated into workflows for high-throughput screening, mechanistic studies, and combinatorial drug assays. For in vitro experiments, prepare stock solutions in DMSO, optionally warming or sonicating to enhance solubility. Store aliquots at -20°C for several months; avoid repeated freeze-thaw cycles. Typical working concentrations range from 5 to 50 μM for cell culture assays. For in vivo mouse studies, administer intraperitoneally at 15 mg/kg daily for at least two days, as per validated xenograft protocols (Optimizing Neuroblastoma Assays—this article provides updated solubility and stability data not covered previously). Always confirm ALK and/or IGF1R expression in the model system before application.

Conclusion & Outlook

AZD3463 is a validated, high-affinity oral ALK/IGF1R inhibitor that enables researchers to dissect and therapeutically target the PI3K/AKT/mTOR axis in neuroblastoma and other ALK-driven cancers. Its efficacy against resistance mutations and in combination with chemotherapeutics marks it as a next-generation tool for translational oncology research. Ongoing studies may further expand its applications across solid and hematologic malignancies. For additional details, visit the AZD3463 ALK/IGF1R inhibitor product page from APExBIO.